Bookrunner Barclays and co-managers Wedbush PacGrow and Griffin assist
By Devika Patel
Knoxville, Tenn., Sept. 26 - Fibrocell Science, Inc. priced a $45.1 million public offering of stock with a $6.77 million greenshoe in a prospectus supplement filed Thursday with the Securities and Exchange Commission. The deal was announced Wednesday.
The company will sell 11 million common shares at $4.10 apiece. The price per share is a 17.84% discount to the Sept. 25 closing share price of $4.99.
Intrexon Corp. will invest about $10 million.
Barclays is the bookrunning manager.
Settlement is expected Oct. 1.
Proceeds will be used for Phase III clinical trials for additional azficel-T indications, to progress collaboration programs with Intrexon Corp. and for working capital and general corporate and administrative expenses.
Fibrocell is a biotechnology company based in Exton, Pa.
| Issuer: | Fibrocell Science, Inc.
|
| Issue: | Common shares
|
| Amount: | $45.1 million
|
| Greenshoe: | $6,765,000
|
| Shares: | 11 million
|
| Price: | $4.10
|
| Warrants: | No
|
| Bookrunner: | Barclays
|
| Co-managers: | Wedbush PacGrow Life Sciences and Griffin Securities
|
| Investor: | Intrexon Corp. (for about $10 million)
|
| Announcement date: | Sept. 25
|
| Pricing date: | Sept. 26
|
| Settlement date: | Oct. 1
|
| Stock symbol: | NYSE: FCSC
|
| Stock price: | $4.99 at close Sept. 25
|
| Market capitalization: | $115.58 million
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
